Background/Aims: Cardiac fibrosis is an important cardiac remodeling event that can ultimately lead to the development of severe arrhythmia and heart failure. MicroRNAs (miRNAs) are involved in the pathogenesis of many cardiovascular diseases. Here, we aimed to investigate the effects of caveolin-3 (Cav3) on the pathogenesis of cardiac fibrosis and the underlying molecular mechanisms. Methods: Cav3 expression was decreased in cardiac fibrosis in vivo and in vitro model. To investigate the role of Cav3 in cardiac fibrosis, we transfected cardiac fibroblasts (CFs) with the siRNA of Cav3 and Cav3-overexpressing plasmid. The collagen content and proliferation of CFs were detected by qRT-PCR, western blot, MTT, and immunofluorescence. A luciferase reporter gene assay and gain/loss of function were used to detect the relationship between miR-22 and Cav3. Results: Cav3 depletion in CFs induced an increase in collagen content, cell proliferation, and phenotypic conversion of fibroblasts to myofibroblasts. Conversely, Cav3 overexpression in CFs was shown to inhibit angiotensin II-mediated excessive collagen deposition through protein kinase C (PKC)ε inactivation. Cav3 was experimentally confirmed as a direct target of miR-22, containing two seed binding sites in its 3′-untranslated region, and miR-22 was demonstrated to be significantly upregulated in the ischemic border zone in mice after myocardial infarction and in neonatal rat CFs pretreated with angiotensin II. miR-22 overexpression increased CFs proliferation, and collagen and α-smooth muscle actin levels in CFs, while the knockdown of endogenous miR-22 decreased
Here, we hypothesized that Cav3 regulates cardiac fibrosis, PKCε at least partially mediates the fibrosis-regulating property of Cav3, and that miR-22 controls Cav3 cellular levels.
Materials and Methods
Mouse model of MI Male Kunming mice (weighing 20~25 g) underwent the ligation of the left descending anterior coronary artery (LAD) to establish the MI model [48] . All experiments were performed according to the guiding principles of Laboratory and Animal Care Committee of the Harbin Medical University (Harbin, China). Four weeks after the ligation, hearts were rapidly removed and prepared for Masson staining or other experimental interventions. All protocols were performed in accordance with the Guide for the Care and Use of Laboratory Animals, published by the US National Institutes of Health (NIH Publication No.85-23, revised 1996).
Rat cardiac fibroblast culture and the cellular model of cardiac fibrosis
Cardiac fibroblasts were isolated from the neonatal Sprague-Dawley rats (1~3 days old), as previously described [49] . The cells were cultured in Dulbecco's Modified Eagle Medium (DMEM; Biological Industries, Kibbutz BeitHaemek, Israel) with 10% fetal bovine serum (FBS; Biological Industries) and incubated at 37°C in the humidified atmosphere with 5% CO 2 . After 48 h, second and third passage cardiac fibroblasts were incubated in the serum-free DMEM for 4 h, which was followed by the addition of AngII (100 nM), and additional incubation for 48 h to stimulate cardiac fibrogenesis.
qRT-PCR
Total RNA was isolated from cardiac fibroblasts using Trizol reagent (Invitrogen, Carlsbad, USA) according to the manufacturer's protocols. Total RNA (1 μg) was used for synthesizing first-strand cDNA using cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, USA). qRT-PCR was performed with SYBR Green Mix kit (Applied Biosystems) according to the manufacturer's instructions. The relative RNA levels were calculated using the ∆∆ Ct method. GAPDH levels served as an internal control. miR-22 expression was assessed using the qRT-PCR miRNA Detection Kit (Applied Biosystems), with U6 levels as an internal control. The primer sequences used for the amplification are shown in Table 1 .
Transfection procedures
Cardiac fibroblasts were seeded in six-well plates. After serum-starving the cells for 4 h, miR-22 (Gene Pharma, Shanghai, China) and Cav3 siRNA (siCav3; Gene Pharma, Shanghai, China) were transfected into the cardiac fibroblasts using X-treme, according to the manufacturer's instructions (Roche Molecular Biochemicals, Basel, Switzerland). The transfection efficiency was measured by qRT-PCR. The sequences we tansfected were as follows: miR-22, sense: 5′-AAGCUGCCAGUUGAAGAACUGU-3′ and antisense: 5′-AGUUCUUCAACUG-GCAGCUUUU-3′; AMO-22:
5′ -UUCUUCGAACGU-GUCACGUTT-3′ and antisense:  5 ′ -ACG U GAC ACG U U CG GAGA-ATT-3′; siCav3, sense: 5′-GCAG-CAACAUUAAGGUGGUTT-3′  and  antisense: 5′-ACCACCUUAAU-GUUGCUGCTT-3′; NC (for siRNA), sense:
5′-UUCUUCGAACGUGU-CACGUTT-3′ and antisense: 5′-AC-GUGACACGUUCGGAGAATT-3′. 
Western blotting
Total proteins were extracted from cardiac fibroblasts. After transfection or other treatments, the cells were lysed with 20 μL of RIPA Buffer (Roche Molecular Biochemicals, Basel, Switzerland), and protein concentrations were detected using BCA kit (Beyotime, Shanghai, China), according to the manufacturer's guidelines. Protein samples (20~40 μg) were separated on a SDS-PAGE gels, and transferred to nitrocellulose membranes. After blocking the membranes with 5% skim milk in phosphate-buffered saline (PBS) for 1 h at room temperature, the membranes were probed with anti-Cav3 (Santa Cruz Biotechnology, California, USA), anti-α-SMA (Abcam, Cambridge, USA), anti-PKCε (PeproTech, New Jersey, USA), anti-pPKCε (Santa Cruz Biotechnology, California, USA), and anti-β-actin (Zhongshanjinqiao, Beijing, China) antibodies at 4°C overnight. The nitrocellulose membranes were washed with PBST (PBS containing 0.5% Tween 20) three times for 7 min each, which was followed by the incubation with a fluorescence-labelled secondary antibody (IRDye700/800 mouse and rabbit antibodies) (Santa Cruz Biotechnology, California, USA). Protein levels were determined using Odyssey infrared scanning system (LI-COR Biosciences, Lincoln, USA) and the band intensities were quantified using ImageJ software.
Masson trichrome staining
The hearts of MI mice were rapidly removed after sacrifice, and the infarct border zone was carefully dissected and immediately immersed in 4% neutral buffered formalin for 24 h. Afterwards, paraffinembedded slices were stained with Masson trichrome stain. Collagen fibers were stained blue and cardiac tissue morphological changes were examined under a light microscope.
Luciferase reporter assay
For the luciferase assay, the luciferase reporter plasmids, together with 20 μmol/L of miR-22, AMO-22, or NC miRNA, and 0.5 μg psi-CHECK2 target DNA were transfected into HK293T cells (seeded at 50~60% confluence). Following 48 h incubation, luciferase activity was detected using the Dual luciferase reporter assay kit (Promega, Wisconsin, USA) on a luminometer (Promega E5331), according to the manufacturer's specification. Base-pair substitutions of mutations were performed using direct oligomer synthesis for the miR-22 bindings sites in the 3′-UTR of the Cav3 gene. All constructs were confirmed by sequencing.
Immunofluorescence staining
Cultured rat cardiac fibroblasts attached to aseptic glass coverslips were washed with PBS five times and fixed in 4% paraformaldehyde for 15 min. Afterwards, the cells were incubated with Triton X-100 at 37°C for 20 min to allow membrane penetration, and this was followed by three washes with PBS and incubation with goat serum (blocking solution) at 37°C for 30 min. The samples were then incubated with a diluted anti-α-SMA antibody (Abcam) at 4°C overnight, followed by the incubation with FITC-conjugated goat anti-rabbit antibody for 90 min. DAPI (Roche Molecular Biochemicals) was used to stain cell nuclei. Immunofluorescence staining was examined under a confocal laser microscope (Olympus, Tokyo, Japan).
Cell viability assay
Cell viability was measured by MTT assay. Cardiac fibroblasts were seeded in the 96-well plates at a density of 5 × 10 3 /well. After 48 h, cardiac fibroblasts were incubated in the serum-free DMEM for 4 h. AngII or transfection reagent was added to the cells. Forty-eight hours after incubation, cardiac fibroblasts were treated with 5 mg/mL MTT (20 µL/well) for 4 h. After DMEM was carefully removed, DMSO (200 µL/well) was added, followed by 15-min shaking. The absorbance was measured at 570 nm using an Infinite 200PRO microplate spectrophotometer (Tecan, Salzburg, Austria), and each measurement was obtained in triplicate.
Relative absorbance values (normalized to the control) were used as an indication of cell viability.
Transfection of cells with Cav3 plasmid
Neonatal rat cardiac fibroblasts were seeded in six-well culture plates. After serum-starving the cells for 4 h, cardiac fibroblasts were transfected with the Cav3-overexpressing plasmids, and this gene was transiently overexpressed using the X-treme GENE siRNA Transfection Reagent (Roche Molecular Biochemicals), according to the manufacturer's protocol. Following the different treatments, total RNA and protein samples were extracted from the cells for qRT-PCR and western blot analysis. 
Statistics
Quantitative data were reported as mean values ± standard error of mean (SEM), and differences between groups were compared using one-way analysis of variance (ANOVA). P < 0.05 was considered statistically significant.
Results

Cav3 expression is downregulated in ischemic myocardia and AngII-treated cardiac fibroblasts
Masson staining results showed the development of cardiac fibrosis, with the considerable deposition of collagen in the myocardia of MI mice but not in the Sham group (Fig. 1a) . Western blot results showed that α-smooth muscle actin (α-SMA) levels were increased in the MI hearts compared with those in the Sham group (Fig. 1b) . The expression of Cav3 at both mRNA and protein levels in the border zone of the infarcted myocardia was shown to be considerably lower in the MI mice, compared with that in the same region of the Sham group hearts (Fig. 1c and 1d) .
In the cultured neonatal cardiac fibroblasts, AngII (100 nM) treatment induced the increase in the mRNA levels of cardiac fibrosis markers Col1a1 and Col3a1, and Mmp9 (Fig. 1e) . MTT assay results revealed that the percentage of viable cardiac fibroblasts considerably increased after AngII treatment (Fig. 1f) . Immunofluorescence analyses demonstrated that AngII treatment upregulated α-SMA expression in cardiac fibroblasts in vitro (Fig. 1g) . In agreement with the results obtained in vivo, Cav3 
levels were decreased at both mRNA (Fig. 1h ) and protein levels (Fig. 1i) in the presence of AngII.
Cav3 downregulation shows pro-fibrotic effects
Furthermore, we examined the effects of Cav3 silencing on cardiac fibroblasts and the development of fibrosis. The data presented in Fig. 2a shows that the treatment with Cav3 small interfering (siRNA; siCav3) induced the increase in Col1a1 (2.5-fold, compared with the untreated control) and Col3a1 (2.1-fold) expression in cardiac fibroblasts, whereas the negative control construct (siNC) did not affect the expression of these genes. Moreover, Cav3 knockdown resulted in a 21% increase in cardiac fibroblast viability, compared with that of the cardiac fibroblasts transfected with siNC (Fig. 2b) . The expression of α-SMA was shown to be increased in cardiac fibroblasts treated with siCav3 (Fig. 2c) . We confirmed that Cav3 expression was successfully silenced using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR; Fig. 2d ).
To confirm our results further, we used gain-of-function approach, by constructing a plasmid harboring the Cav3 gene. As presented in Fig. 2e , cardiac fibroblasts transfected with Cav3-carrying plasmid were shown to have 1.8-fold higher Cav3 protein level than those transfected with the empty vector. Cav3 overexpression at 48 h mitigated AngIIinduced increasement in Col1a1 (by 43.1%) and Col3a1 (by 26.2%) expression (Fig. 2f) . MTT assay results demonstrated that the overexpression of Cav3 reduced the viability of cardiac fibroblasts (Fig. 2g) . Immunofluorescence analyses showed that the overexpression of Cav3 led to the inhibition of AngII-induced α-SMA expression in cardiac fibroblasts (Fig. 2h) .
PKCε mediates Cav3 inhibition-induced development of fibrosis
PKC is a family of protein kinases, which play critical roles in the regulation of cardiac functions and pathophysiological processes [50] [51] [52] . Here, we demonstrated that an activator of PKCε, FR236924, leads to an increase in Col1a1 and Col3a1 transcript levels by 58.1% and 98.6%, respectively ( Fig. 3a and 3b) . Conversely, PKCε inhibitor peptide inhibited AngIIinduced upregulation of Col1a1 and Col3a1 expression by 58.2% and 78.6%, respectively ( Fig. 3a and 3b) . Moreover, FR236924 was shown to promote cardiac fibroblast proliferation, while PKCε inhibitor peptide inhibited AngII-induced proliferation of these cells (Fig. 3c) . As presented in Fig. 3d , α-SMA expression was shown to be increased following the treatment of cardiac fibroblasts with FR236924, whereas AngII-induced α-SMA upregulation in these cells decreased after PKCε inhibitor peptide treatment. Cav3 was reported to interact with several signaling proteins localized in the caveolae, such as PKCε, δ, and α [40] [41] [42] . Our western blot data (Fig. 3e) showed that the phosphorylation of PKCε at Ser 729 (pPKCε) increased after Cav3 silencing of in cardiac fibroblasts, while pPKCε levels decreased with the increase in Cav3 levels.
miR-22 is a key regulator of Cav3 expression and function
To determine the upstream regulators of the described processes, since miRNAs have recently been shown to participate in regulation of the expression of genes involved in cardiac fibrogenesis [53] [54] [55] , we attempted to identify miRNAs that may target Cav3. TargetScan miRNA database analysis identified miR-22 as a candidate regulatory miRNA, since the 3′-UTR of the Cav3 gene contains two putative binding sites for miR-22 seed motif, which are highly conserved across the species, including rats, mice, and humans (Fig. 4a) . We determined the expression levels of miR-22 in MI and Sham hearts, and our results demonstrated that miR-22 levels increased in the border zone in the MI mice and in the cardiac 
fibroblasts treated with AngII, which was negatively correlated with Cav3 expression (Fig. 4b  and 4c ). The transfection of miR-22 mimic into cardiac fibroblasts decreased he mRNA and protein levels of Cav3 by nearly 33.2% and 41.2%, respectively, compared with those in the cells treated with the NC miRNA (Fig 4d and 4e) , while these effects were inhibited by the co-transfection of cells with AMO-22 (miR-22 antisense inhibitor). Furthermore, luciferase reporter gene assay was performed in order to validate Cav3 as a direct target of miR-22. We transfected the cells with the psiCHECK-2 vector carrying the wild-type (WT) or mutated sequences (MuT) found in the 3′-UTR of Cav3 (Cav3/3′-UTR) (Fig. 4f) . As presented in Fig. 4g , the co-transfection of cells with miR-22 mimic substantially reduced (by 56.4%) luciferase activity induced by the WT psiCHECK-2. The observed inhibition was decreased (by 27.7%) when the vector carrying MuT at the nucleotide positions 236-243 in Cav3/3′-UTR was used, while positioning the mutations at nucleotides 588-594, miR-22 treatment reduced luciferase activity by 40.1%, compared with that in the control. Using a double-mutation construct, we demonstrated that miR-22 lost the ability to affect luciferase activity (Fig. 4g) . Successful delivery of miR-22 mimic and AMO-22 into the cardiac fibroblasts was confirmed by qRT-PCR analysis (Fig. 4h) . Induced expression of miR-22 in cardiac fibroblasts considerably upregulated Col1a1 (2.4-fold) and Col3a1 (2.1-fold) expression levels, compared with those in the untreated cells (Fig. 5a) , and led to an increase in the number of cardiac fibroblasts (Fig. 5b) . In contrast to this, AMO-22 inhibited AngII-induced cardiac fibroblast proliferation (Fig. 5c ). Immunofluorescence analysis showed that the overexpression of miR-22 induced the expression of α-SMA cardiac fibroblasts in vitro (Fig. 5d) . 
Discussion
To the best of our knowledge, here we presented for the first time the anti-fibrotic properties of Cav3, showing that Cav3 levels are considerably decreased in a mouse model of MI and in AngII-treated cardiac fibroblasts in vitro. Cav3 downregulation was shown to promote cardiac fibrosis induced by MI or AngII. This induced the phosphorylation of PKCε, which in turn led to the development of cardiac fibrosis. Furthermore, we demonstrated that miR-22 was markedly upregulated after MI and in the AngII-treated cardiac fibroblasts, which was shown to lead, at least partially, to the downregulation of Cav3, demonstrating that Cav3 represents a direct target of miR-22. Additionally, miR-22 overexpression was shown to induce cardiac fibrosis rate. Therefore, we showed a novel molecular mechanism underlying cardiac fibrosis and elucidated the role of miR-22/Cav3/pPKCε signaling in cardiac fibrosis (Fig 6) .
Cav3 is the main component of caveolae in cardiac cells, and it was shown to play an important role in maintaining cardiac function [56] and intracellular calcium homeostasis [57] . Furthermore, its dysregulation is involved in the development of arrhythmia, myocardial hypertrophy, and myocardial ischemia/reperfusion injury [17] [18] [19] . However, no previous studies elucidated the regulatory role of Cav3 during the development of cardiac fibrosis. In this study, we showed that Cav3 silencing induces the proliferation and differentiation of cardiac fibroblasts into myofibroblasts, and the accumulation of collagen. However, Cav3 overexpression may rescue AngII-induced pathological myofibroblast formation, indicated by α-SMA expression alterations, proliferation, indicated by the changes in the cardiac fibroblast number, and collagen deposition. Therefore, our findings show that Cav3 may represent an anti-fibrotic factor. The changes in the relationships between Cav3 and its interacting partners may contribute to the development of several cardiac pathological conditions. For example, the stabilization Cav3/LG-EMMPRIN complex plays a significant role in the cardioprotective effects of Nitric oxide against ischemia-reperfusion [58] . Hypoxic preconditioning promotes rapid association of PKCε, PKCδ, and PKCα with the Cav-enriched plasma membrane microdomain of cardiac myocytes, and PKCε via a direct molecular interaction with Cav3 [26] . PKCε is essential for the adhesion and migration of cells [59] , and the lack of PKCε results in an increased collagen deposition and impaired diastolic function [60] . Inagaki et al [61] showed that the increase in PKCε expression promotes the . proliferation of cardiac fibroblasts and induces cardiac fibrosis. Here, we demonstrated that collagen deposition and cardiac fibroblasts proliferation increased with PKCε activation and decreased upon PKCε inhibition. PKCε phosphorylation was shown to increase following the silencing of Cav3, while this phosphorylation decreased after Cav3 overexpression.
The data obtained here indicate that the upregulation of miR-22 is responsible, at least partially, for the downregulation of Cav3 during cardiac fibrosis development. miR-22 over- On this basis, our second innovation is to clarify the mechanism of Cav3 regulating cardiac fibrosis, and answered the question why Cav3 changed and how Cav3 worked in cardiac fibrosis. Here we reported that Cav3 regulates cardiac fibrosis by regulating phosphorylation of PKCε, and miR-22 could inhibit the expression of Cav3, which provides us with new targets and new ideas for the treatment of cardiac fibrosis in the future.
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